Borget, I., Cadranel, J., Pignon, J. P., Quoix, E., Coudert, B., Westeel, V., Dansin, E., Madelaine, J., Madroszyk, A., Friard, S., Daniel, C., Morin, F., Chouaid, C., & ERMETIC Collaborative Group (2012).
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. The European respiratory journal, 39(1), 172–179.
https://doi.org/10.1183/09031936.00201210